Washington COVID-19 Biorepository Expands Sample Types

The current COVID19 pandemic showcases a critical need to accelerate the development and validation of quality diagnostic products for COVID-19. To support this effort, PATH, a global health non-profit, has created a growing biorepository of qualified clinical samples to support and accelerate the development and validation of quality in-vitro diagnostics.

Roger Peck cataloging the first set of samples in the biorepository. 

The Washington COVID-19 biorepository now includes convalescent plasma to accelerate the development of antibody assays. Convalescent plasma samples allow manufacturers to assess the performance of several designs and prototypes under development. By running multiple replicates of these relatively accessible specimens on each prototype, diagnostics developers can generate large amounts of performance data allowing for better assessment of the technology.

Click here to read more.

    By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

    The 'OpenSpecimen Biobanking LIMS RFP Q&A' Excel is emailed to you.
    Feel free to Contact Us for any questions.

    Srikanth Adiga,
    C.E.0, OpenSpecimen
    Email: sri@krishagni.com


      Avoid Gmail, Yahoo, etc. please.

      By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

        By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

        The Features PDF has been emailed to you.
        Feel free to "Schedule a Demo" or "Contact Us" for any questions.

        Srikanth Adiga,
        C.E.0, OpenSpecimen
        Email: sri@krishagni.com

          By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.